← All indications
Leukemia, Biphenotypic, Acute
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.
Drugs by status
Approved for this indication (2)
Phase 3 trials (10)
Phase 2 trials (49)
- allopurinol
- cladribine
- azacitidine
- vitamin d3
- mercaptopurine
- allogeneic natural killer cells
- urea
- sorafenib
- venetoclax
- bendamustine
- busulfan
- clofarabine
- doxorubicin
- hemopoietic stem cell
- idarubicin
- Filgrastim
- nivolumab
- lirilumab
- Flotetuzumab
- allogeneic stem cells
- vincristine
- ibrutinib
- pegaspargase
- ipilimumab
- allogeneic hematopoietic stem cells
- ruxolitinib
- sirolimus
- cyclosporine
- Anti-thymocyte Globulin (Rabbit)
- bortezomib
- +19 more
Organizations
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (15)
- Bristol-Myers Squibb
- Syndax Pharmaceuticals
- Center for International Blood and Marrow Transplant Research
- National Heart, Lung, and Blood Institute (NHLBI)
- National Marrow Donor Program
- University of Washington
- Johns Hopkins University
- Medical College of Wisconsin
- Stanford University
- University of South Florida
- Pavlov First Saint Petersburg State Medical University
- City of Hope National Medical Center
- Mesoblast, Inc.
- University of Texas at Houston
- St. Jude Children's Hospital
Organization Involved with Phase 1 Indications (8)